Loading
A phase 2 trial of Alcestobart run by BeiGene, completed.
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT05909904 by BeiGene, with 160 participants enrolled, started 2023-08-02. Conditions recorded: Head and Neck Squamous Cell Carcinoma and Head and Neck Cancer. Interventions recorded: Tislelizumab, BGB-A425 and LBL-007.
Shares Alcestobart, Nanjing Leads Biolabs, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/